Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.82 |
| ▸ | BCR | P11274 | 4/20 | 0.82 |
| ▸ | SRC | P12931 | 2/20 | 0.82 |
| ▸ | EGFR | P00533 | 2/20 | 0.78 |
| ▸ | PRKACA | P17612 | 1/20 | 0.78 |
| ▸ | PRKACG | P22612 | 1/20 | 0.78 |
| ▸ | PRKACB | P22694 | 1/20 | 0.78 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.73 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.72 |
| ▸ | PLK1 | P53350 | 1/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.62 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.62 |
| ▸ | GSK3B | P49841 | 2/20 | 0.62 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.62 |
| ▸ | CDK4 | P11802 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823915 | 0.93 | CAMK2D (0.82) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL2944432 | 0.91 | ABL1 (0.82) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL27444270 | 0.91 | PLK1 (0.78) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL1789 | 0.90 | ABL1 (1.00) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL1465 | 0.88 | ABL1 (1.00) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL5471964 | 0.87 | ABL1 (0.71) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL14530851 | 0.87 | PLK1 (0.75) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL1593016 | 0.85 | PRKCD (0.79) | ABL1BCRSRCEGFRCAMK2D | |
| SCHEMBL4903508 | 0.84 | ABL1 (0.67) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL12801709 | 0.84 | CAMK2D (1.00) | ABL1BCRSRCEGFRPRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440663-B2 | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008124085-A2 | METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | ABL1 14/4885BCR 1633/4885SRC 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.